Cecchini M, Pilat MJ, Uboha N, Azad NS, et al. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025;131:e35755.
PMID: 39917990